CIZ

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced a further update regarding the Company’s put option to sell its 5% economic interest and royalty sharing agreement in

Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, have announced recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced a further update regarding the Company’s put option to sell its 5% economic interest and royalty sharing agreement in

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced an expansion of its current research programme with the University of York to develop its CIZ1B biomarker technology for early

Cizzle Biotechnology (LON:CIZ), the UK-based diagnostics developer, has announced that it has conditionally raised gross proceeds of £350,000 (before expenses of £17,500) by way of the issue of 16,666,667 new Ordinary

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, has announced its audited results for the year ended 31 December 2022. Chair’s Statement The Group has continued throughout 2022 in

Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced that following successful results from its current research programme with the University of York, due to end this year, that it

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of

Cizzle Biotechnology plc (LON:CIZ), the UK-based diagnostics developer, notes the announcement by Conduit Pharmaceuticals Limited that they intend to become a publicly traded company on NASDAQ in the USA via